PHAT Phathom Pharmaceuticals, Inc.
Financings ·
Phathom priced 6,875,000 shares at $16.00 plus pre-funded warrants for 1,250,078 shares, for a public offering of $129,999,998. Its cash fell from $297.3 million at the end of 2024 to a preliminary $130 million at the end of 2025, and the company expects operating profit only in the second half of 2026, excluding stock-based compensation.
We have not published a story on Phathom Pharmaceuticals yet. When there is news, it will appear here.
Phathom Pharmaceuticals is a commercial-stage biopharmaceutical company focused on commercializing and developing treatments for gastrointestinal diseases. Its approved products, VOQUEZNA, VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK, contain vonoprazan, an oral potassium-competitive acid blocker. The company says VOQUEZNA is the only PCAB approved for marketing and sale in the United States. Phathom began U.S. commercialization in November 2023, with VOQUEZNA for erosive gastroesophageal reflux disease and H. pylori infection, and the two PAK products for H. pylori infection. The FDA approved VOQUEZNA for relief of heartburn associated with non-erosive GERD in July 2024. Vonoprazan was originally developed by Takeda Pharmaceutical Company Limited, from which Phathom licensed U.S., European and Canadian rights in 2019. Phathom independently commercializes its products in the United States. Most of its revenue in 2025 came from VOQUEZNA sales, and the company reports growth in prescription volume and prescriber adoption.
| Product or program | What it is | Stage |
|---|---|---|
| VOQUEZNA | Vonoprazan acid blocker for erosive GERD and H. pylori infection | Approved in the US |
| VOQUEZNA DUAL PAK and TRIPLE PAK | Vonoprazan packs for H. pylori infection | Approved in the US |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $175.1 million | $55.3 million |
| Research and development | $32.8 million | $34.1 million |
| Net income (loss) | -$221.2 million | -$334.3 million |
| Cash from operations | -$166.8 million | -$266.8 million |
| Cash and equivalents | $130.0 million | $297.3 million |
Our latest story on this, dated Jan 7, 2026: "Phathom Pharmaceuticals prices stock and pre-funded warrant offering at $16.00 a share". The story links the filing or release it is based on. Read the story.
Phathom Pharmaceuticals, Inc. trades under the ticker PHAT on NASDAQ.
Phathom Pharmaceuticals, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Phathom Pharmaceuticals, Inc. is 1783183. Its filings are on SEC EDGAR.
80,900,934 shares as of 2026-07-27, per the cover page of its 10-Q filed 2026-07-30.
Our directory records Phathom Pharmaceuticals, Inc. under United States.
Our directory classifies Phathom Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Phathom Pharmaceuticals, Inc. is US71722W1071.
aibio.space lists Phathom Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Phathom Pharmaceuticals is a commercial-stage biopharmaceutical company focused on commercializing and developing treatments for gastrointestinal diseases. Its approved products, VOQUEZNA, VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK, contain vonoprazan, an oral potassium-competitive acid blocker.
VOQUEZNA: Vonoprazan acid blocker for erosive GERD and H. pylori infection Stage: Approved in the US.
VOQUEZNA DUAL PAK and TRIPLE PAK: Vonoprazan packs for H. pylori infection Stage: Approved in the US.
$175.1 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Phathom Pharmaceuticals, Inc. reported a net loss of $221.2 million for the fiscal year ended Dec 31, 2025, and used $166.8 million of cash in operations, per its annual report to the SEC.
Reported a financing. SEC Form 424B5. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio